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Abstract: Childhood-onset craniopharyngiomas are partly cystic embryonic malformations 
of the sellar/parasellar region. The therapy of choice in patients with favorable tumor 
localization is complete resection with a specific focus on maintaining optical and 
hypothalamic neuroendocrine functions. In patients with unfavorable tumor localization (i.e., 
hypothalamic involvement), a limited hypothalamus-sparing surgical strategy followed by 
local irradiation is recommended. Involvement and/or surgical lesions of posterior 
hypothalamic areas cause major neuroendocrine sequelae. The overall survival rates are high 
(92%) but neuroendocrine disorders such as obesity and metabolic syndrome due to 
involvement and/or treatment-related hypothalamic lesions have major negative impact on 
survival and quality of life. Recurrences and progressions are frequent post-surgical events. 
Because irradiation is efficient in preventing tumor progression, appropriate timing of  
post-surgical irradiation is currently under investigation in a randomized multinational trial 
(KRANIOPHARYNGEOM 2007). Childhood-onset craniopharyngioma should be 
recognized as a chronic disease requiring treatment and constant monitoring of the clinical 
and quality of life consequences, frequently impaired due to neuroendocrine disorders, by 
experienced multidisciplinary teams in order to provide optimal care of surviving patients.  
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1. Introduction 
Childhood-onset craniopharyngiomas (CP) are rare embryonic malformations of the sellar and 
parasellar area with low histological grade (WHO I°). Despite high survival rates (87%–95% in  
recent series), quality of life (QoL) is frequently impaired in long-term survivors due to mainly 
neuroendocrine sequelae caused by the anatomical proximity of the tumor to the optic nerve and to the 
hypothalamic-pituitary axes [1–7]. Any clinical significant improvement in the prognosis of CP 
patients will require the development of risk adapted neurosurgical and radiooncological treatment 
strategies in a multidisciplinary setting that provides medical as well as psychosocial support for these 
patients [8,9]. Due to the rareness of the disease, high survival rates, and adverse QoL effects, recent 
multicenter cooperation has already led to beneficial results in regard to long-term neuroendocrine 
deficits [2,10–12]. 
2. Epidemiology and Pathology 
CP is a non-glial intracranial tumor derived from a malformation of embryonal tissue [13]. CP 
incidence is 0.5–2 cases per million persons per year, with 30%–50% of all cases presenting during 
childhood and adolescence [14,15]. In childhood and adolescence, its histological type is usually 
adamantinomatous with cyst formation [16,17]. More than 70% of the predominantly childhood 
adamantinomatous type of CP bear a mutation of the β-catenin gene [18]. Recently, a new mouse 
model of adamantinomatous childhood CP due to an activation of the Wnt signaling pathway was  
published [19].  
3. Clinical Manifestations at the Time of Diagnosis 
The diagnosis of CP is often made late—sometimes, years after the initial appearance of  
symptoms [20,21]—with the clinical picture at time of diagnosis often dominated by non-specific 
manifestations of intracranial pressure. Further primary manifestations are visual impairment  
(62%–84%) and endocrine deficits (52%–87%) (Figure 1). Endocrine deficits are frequently caused by 
disturbances to the hypothalamic-pituitary axes and affect growth hormone secretion (75%), 
gonadotropins (40%), adrenocorticotropic hormone (ACTH) (25%), and thyroid-stimulating hormone 
(TSH) (25%). At the time of diagnosis, 40%–87% of patients present with at least one hormonal  
deficit [4,22–24].  




Figure 1. Manifestations before diagnosis of craniopharyngioma in children and 
adolescents. Frequency of occurrence of each manifestation before diagnosis (blue 
columns) and frequency of occurrence as the initial manifestation (red columns). The 
median time (months) from the appearance of each initial manifestation until diagnosis is 
indicated above each red column. In the overall group, the median time from the initial 
manifestation of disease until diagnosis was 12 months, with a range of 0.01–96 months. 
Modified from [20] with kind permission from Springer. 
4. Imaging Studies 
Both computerized tomography (CT) and magnetic resonance imaging (MRI) reveal that CP is 
typically a cystic tumor of the intra- and/or parasellar region. The most common location is suprasellar, 
with an intrasellar portion; only 20% of CPs are exclusively suprasellar and even less (5%) exclusively  
intrasellar [25,26]. CT is the only way to definitively detect or exclude calcifications in CP tissue, 
which is found in approximately 90% of these tumors (Figure 2).  
5. Treatment Strategies 
5.1. Neurosurgery—Strategies and Effects 
For favorably localized CP (i.e., without involvement of hypothalamic or optical structures), the 
preferred treatment of choice is an attempt at complete surgical resection with preservation of visual 
and hypothalamic function [27–29]. For unfavorably located tumors too close to or too entangled with 
the optic nerve and/or hypothalamic structures, controversy exists over whether complete resection 
should still be attempted or whether a planned limited surgical resection should be performed [2,30,31]. 
Many authors take a critical view of planned radical resection in these cases because of the risk of 
surgically induced deficits (mainly hypothalamic) and the high rate of recurrence especially in infants 
and small children despite apparent complete resection [32,33]. Recurrences at ectopic location are 
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of patients, the progression rate after incomplete resection followed by radiotherapy is 21% [35]. 
Elowe-Gruau et al. [36] recently published their results of a single institution study at Necker, Paris, 
France, showing that a hypothalamus-sparing surgical strategy decreased the rate of severe long-term 
obesity in survivors without increasing their risk for local relapses when compared with a historical 
cohort treated before 2002 at the same experienced institution with a radical surgical approach [36]. 
 
Figure 2. Degree of obesity in relation to the location of childhood-onset 
craniopharyngioma. In both patients, craniopharyngioma (as indicated by arrow on 
magnetic resonance imaging before surgery) could be completely resected. Both patients 
had complete hypopituitarism after surgery requiring endocrine substitution of all 
hypothalamic-pituitary axes. The patient depicted in (B) developed severe obesity due to 
hypothalamic lesions of suprasellar parts of craniopharyngioma (C). The patient depicted 
in (A) presented with a small tumor confined to the sellar region (D). After complete 
resection, she maintained a normal weight without any eating disorders. Modified from [20], 
with kind permission of Springer. 
However, the published literature to date [32,36–43] has not settled the controversy over the 
optimal treatment strategy for CP. Above all, effects of the chosen treatment sequence  
(progression-contingent irradiation of residual tumor vs. immediate irradiation) on QoL and 
neuroendocrine function are unclear based on the retrospective data published to date.  
Any discussion of treatment and follow-up strategies must take into account the neuroendocrine 
sequelae and QoL experienced by CP patients after treatment. Follow-up studies of QoL in children 
after complete resection of CP revealed that QoL depends on the experience of the operating 
neurosurgeon [44–46]. Daubenbüchel et al. [47] recently published that 20-year overall survival rates 
b a c 
d 
J. Clin. Med. 2015, 4 393 
 
 
were significantly lower in CP patients with initial involvement of hypothalamic structures when 





Figure 3. Kaplan-Meier analyses of overall (A) and progression-free survival rates (PFS)  
(B) depending on preoperative hypothalamic involvement in 177 patients with sellar 
masses (163 childhood-onset craniopharyngiomas, 14 cysts of Rathke’s pouch) recruited in 
the trial Hit Endo. Modified from [47] with kind permission from Bioscientifica. 
5.2. Irradiation 
A conventional, fractionated irradiation target (total) volume dose of 54 Gray has been established 
worldwide [35,48–52]. Clinical outcome data are still very limited for assessing the value of proton  
beam therapy compared to modern photon therapy, as the technique is available in only a few centers. 
95%-CI 
No HI: 0.84–1.0 
HI: 0.76–0.92 
HI, n = 96 (0.84 ± 0.04)
No HI, n = 69 (0.94 ± 0.05) 
p = 0.021
95%-Cl: 
No HI: 0.32–0.86 
HI: 0.52–0.84 p = 0.940
No HI, n = 69 (0.59 ± 0.14)
HI, n = 96 (0.68 ± 0.08) 
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However, proton beam therapy has the potential advantages of better conformation of dose to the 
target volume, sparing of critical structures, reduced integral dose, and lower dose of secondary 
neutrons, which should reduce the risk of secondary malignancies [53,54]. 
6. Neuroendocrine Sequelae 
6.1. Pituitary Deficiencies 
Pituitary hormone deficiencies are common in CP. At the time of diagnosis, 40%–87% of  
children [4,22,23,55] present with at least one hormonal deficit and 17%–27% [4,23,24] have been 
reported to have diabetes insipidus neurohormonalis. The rate of post-surgical pituitary hormone  
deficiencies increases due to the tumor’s proximity or even involvement of hypothalamic-pituitary  
axes [21–24,43,56–58]. Transient post-surgical diabetes insipidus occurs in up to 80%–100% of all  
cases [22,59]. The rate of permanent post-surgical diabetes insipidus ranges between 40% and  
93% [22–24,37,43,46,58–60].  
Growth hormone deficiency has been described at the time of diagnosis in 26%–75% of CP [4,60], 
and impaired growth may occur already years before diagnosis [21]. Growth hormone deficiency 
following treatment for CP is found in about 70%–92% of patients [21,46,61,62]. A positive response 
to growth hormone treatment is seen in most cases [63]. Normal growth in CP patients with proven 
growth hormone deficiency is reported in the literature [64]. In fact, CP patients with hypothalamic 
involvement were found to achieve normal adult height more often than those without hypothalamic 
involvement [21]. Even though this phenomenon of “growth without growth hormone” was described 
in CP almost five decades ago [65], the physiology of growth in these cases is still not fully 
understood—although insulin and/or leptin are suspected to play a compensating role in  
this phenomenon.  
6.2. Hypothalamic Dysfunction 
Symptoms related to hypothalamic neuroendocrine dysfunction, such as obesity, behavioral 
changes, disturbed circadian rhythm and sleep irregularities, daytime sleepiness, and imbalances in 
regulation of body temperature, thirst, heart rate and/or blood pressure have been found at diagnosis in 
35% of CP patients [24]. The rate of neuroendocrine hypothalamic dysfunction dramatically increases 
following radical surgical treatment; in some series up to 65%–80% [24,59]. Even though pre-surgical 
evaluation of hypothalamic damage is difficult both clinically and radiologically [56], tumor 
involvement of the third ventricle or obstructive hydrocephalus are suggestive findings [22]. A three 
level clinical grading system for hypothalamic dysfunction has been suggested based on the degree of 
obesity and hypothalamic tumor involvement [58]. 
Associated with high morbidity, suprachiasmatic CP with hypothalamic involvement are difficult to 
treat. Surgical removal of CP tissue beyond the mammillary bodies (i.e., in the posterior hypothalamic 
area) endangers hypothalamic structures and may cause severe neuroendocrine deficits such as 
hypothalamic obesity [30,46]. With the aid of imaging studies, several reports have indicated that the 
degree of obesity of affected CP patients is positively correlated with the degree of hypothalamic  
damage [46,66–68]. Fjalldal et al. [69] recently published the results of a cross-sectional study of 42 
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patients who were analyzed for cognitive performance and psychosocial health at a median follow-up of 
20 years after diagnosis of CP. The authors observed disturbed attention and impaired processing 
speed in adults with CP when compared with matched normal control. The deficits were most 
pronounced in patients with hypothalamic involvement of CP [69]. Taking these considerations into 
account, novel classifications of pre-surgical involvement and postsurgical lesions of hypothalamic 
structures based on MRI were recently published [28,46]. The classification might help to establish more 
risk adapted surgical strategies (Figure 4) based on a grading of pre-surgical hypothalamic involvement 
and post-surgical hypothalamic lesions. 
6.3. Obesity and Eating Disorders 
Rapid weight gain and severe obesity are the most perplexing neuroendocrine complications due to 
hypothalamic involvement and/or hypothalamic surgical lesions of CP. Weight gain in CP patients  
often occurs years before diagnosis [21], with 12%–19% of patients reported to be obese at  
diagnosis [4,23,59,60]. Weight gain occurs despite adequate endocrine replacement of pituitary 
hormone deficiencies. The hypothalamic disturbance in energy management contributes to the 
development of severe obesity and is exacerbated by factors limiting physical activity such as marked 
daytime sleepiness, disturbances of circadian rhythms, and neurological deficits [70]. The degree of 
obesity frequently increases early after treatment and rapid weight gain typically occurs during the first 
6–12 months after treatment [60,67,71]. Following CP treatment, the prevalence of severe obesity is 
higher, reaching up to 55% [23,37,59,60,64,71–74]. Obesity and eating disorders result in increased 
risks of metabolic syndrome [64] and cardiovascular disease [68], including sudden death events [75], 
multisystem morbidity [76], and mortality [48,59,77–83]. 
Although the relation of severe obesity with hypothalamic lesions is obvious in CP  
patients [67,68,84], the neuroendocrine mechanisms responsible for increased prevalence of 
cardiometabolic complications in these patients are still unclear. It is likely that in case of suprasellar 
extension, hypothalamic neuroendocrine function will be compromised and will remain compromised 
to a certain extent when treated surgically or with irradiation. The hypothalamus plays a predominant 
role in keeping the internal environment stable by synchronizing biological clock mechanisms and 
circadian rhythms [85]. Recent data indicate that an adequate balance of the autonomic nervous system 
equilibrium is crucial for metabolism. It is well known that adipose tissue is richly innervated by 
sympathetic nerve fibers that control lipolysis. Consequently, it appears that lipogenesis is also controlled 
by parasympathetic innervation of adipose tissue originating from separate sympathetic and 
parasympathetic neurons in the periventricular nucleus and suprachiasmatic nucleus [86]. Such a high 
level of differentiation puts the suprachiasmatic nucleus in a key position to balance circadian activity 
of both branches of the autonomous nervous system. Considering the large proportion of CP patients 
with damage to suprasellar structures, it is likely that CP involving hypothalamic areas and/or the 
effects of treatment of these tumors damage the suprachiasmatic hypothalamic nucleus. This in turn 
affects the regulation of central clock mechanisms, which predisposes to neuroendocrine alterations in 
metabolism. Clearly, surgical strategies to preserve hypothalamic integrity are mandatory for the 
prevention of neuroendocrine deficits such as severe obesity owing to hypothalamic lesions (Figure 5). 
 





Figure 4. BMI and MRI imaging at diagnosis and 36 months after surgery in three cases of 
childhood-onset craniopharyngioma (CP) with different grades of hypothalamic 
involvement/lesion. (A,B) CP confined to the intrasellar space (0° no hypothalamic 
involvement (A)/surgical lesion (B)). BMI at diagnosis: −0.11 S.D.; BMI 36 months after 
complete resection: −0.41 S.D. (C,D) CP involving the anterior hypothalamus (I° 
hypothalamic involvement (C)/surgical lesion of the anterior hypothalamic area (D)). BMI 
at diagnosis: −1.75 S.D.; BMI 36 months after complete resection: −0.43 S.D. (E,F) CP 
involving the anterior and posterior hypothalamus (II° hypothalamic involvement 
(E)/surgical lesion of the anterior and posterior hypothalamic area (F)). BMI at diagnosis: 
+6.08 S.D.; BMI 36 months after complete resection: +6.79 S.D. Modified from [46], with 
kind permission from Bioscientifica. 
 




Figure 5. Changes in body mass index (BMI SDS) during first 36 months after diagnosis 
of 117 childhood-onset craniopharyngioma patients recruited inKRANIOPHARYNGEOM 
2000 relative to the extent of surgical hypothalamic lesions (grade 0–2). The horizontal 
line in the middle of the box depicts the median. The edges of the box mark the 25th and 
75th percentile. Whiskers indicate the range of values that fall within 1.5 box-lengths. 
Modified from [46], with kind permission from Bioscientifica. 
When elevated serum leptin levels relative to body mass index were found in CP patients with  
a suprasellar tumor extension [87], researchers suggested that normal appetite inhibition failed to occur 
in these patients due to disruption of hypothalamic receptors that regulates negative feedback loops in 
which leptin, formed in adipocytes, binds to hypothalamic leptin receptors. However, a study involving 
self-assessment by nutritional diaries revealed that hypothalamic obesity also occurs in CP patients 
even when caloric intake is comparable to controls matched for body mass index [88]. 
6.4. Physical Activity and Energy Expenditure 
An analysis of physical activity by accelerometric assessments showed that CP patients demonstrated 
a markedly lower level of physical activity than healthy controls matched for body mass index [88]. 
Markedly increased daytime sleepiness and disturbances of circadian rhythms have been demonstrated 
in patients with severely obese CP [70]. Daytime sleepiness and obesity in these patients were both 
correlated with low nocturnal and early morning melatonin concentrations in saliva. The proposed 
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CP extending to the suprasellar area. Initial experiences with oral melatonin substitution in CP patients 
were promising: melatonin levels normalized and physical activity and daytime sleepiness improved 
significantly [89]. However, data on long-term effects of melatonin substitution on weight 
development and daytime sleepiness have not yet been published. 
Polysomnographic studies in patients with CP and severe daytime sleepiness have revealed sleeping 
patterns typical for hypersomnia and secondary narcolepsy, i.e., frequent “sleep-onset REM phases” 
(SOREM) [72,90,91]. Medication with central stimulating agents (methylphenidate, modafinil) had  
a markedly beneficial effect on daytime sleepiness in these patients [90]. Secondary narcolepsy should 
be taken into consideration as a pathogenic factor in severely obese CP patients. Mason et al. [92] 
treated five pediatric patients with CP and severe hypothalamic obesity with the central stimulating 
agent dextroamphetamine for the purpose of weight reduction. Dextroamphetamine therapy stabilized 
patients’ body mass index. The patients’ parents reported noticeable improvements in their child’s 
physical alertness and activity.  
A decreased metabolic rate, in terms of both resting and total energy expenditure (TEE), has been 
suggested to contribute to weight gain in CP patients. Adults and pediatric patients with childhood-onset 
CP were found to have a lower resting-energy expenditure (REE) compared to controls [67,93,94] that 
was not explained by differences in terms of body composition. The energy intake/REE ratio was 
lower in those with tumors involving the third ventricle [67]. Impaired physical activity might be 
associated with an overall lowering of TEE [67,68,88,93]. Further factors potentially contributing to 
decreased physical activity are neurological and visual deficits, psychosocial difficulties, and increased  
daytime sleepiness. 
6.5. Autonomous Nervous System 
Lustig et al. [95,96] hypothesized that hypothalamic disinhibition of vagal output might be a cause 
of increased β-cell stimulation in CP patients, and that this disinhibition leads to hyperinsulinism and 
severe obesity. The authors therefore studied treatment with the somatostatin analogue octreotide, 
which suppresses β-cell activity [95].  
Several reports [97,98] have hypothesized that decreased physical activity and severe obesity in CP 
patients could be related to impaired central sympathetic output. Roth et al. observed reduced urine 
concentrations of catecholamine metabolites correlating with the degree of obesity and the level of 
physical activity [99]. 
6.6. Appetite-Regulation 
Roth et al. analyzed the gastrointestinal hormones ghrelin and peptide YY and their effect on satiety 
regulation in patients with CP and hypothalamic obesity [100]. Their findings support the hypothesis 
that reduced ghrelin secretion and impaired postprandial suppression of ghrelin in patients with CP and 
severe hypothalamic obesity results in disturbed regulation of appetite and satiety. Serum 
concentrations of peptide YY did not differ between normal weight, obese, and severely obese CP 
patients. A possible pathogenic role of peripheral α-melanocyte-stimulating hormone in CP obesity has 
also been reported [101]. 
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Functional MRI was used in CP patients to examine the hypothesis that hypothalamic damage due 
to the tumor and/or its treatment results in enhanced perception of food reward and/or impaired central 
satiety processing [102]. Following a test meal, controls showed suppression of activation by food cues 
while CP patients showed trends towards higher activation in functional MRI. The authors conclude 
that perception of food cues may be altered in hypothalamic obesity, especially after eating, i.e., in the 
satiated state. The functional MRI approach is encouraging for performing future mechanistic studies 
of the brain response to food cues and satiety in patients with hypothalamic obesity due to CP. 
6.7. Treatment of Hypothalamic Obesity 
Due to disturbances in energy expenditure, appetite-regulation, and central sympathetic output, CP 
patients with hypothalamic obesity typically develop morbid obesity that is mainly unresponsive to 
conventional lifestyle modifications (diet and exercise) [103]. Based on impairment of sympatho-adrenal 
activation manifesting as a reduced hormonal response to hypoglycemia, treating this disorder with 
amphetamine derivates has been suggested [104,105]. Use of dextroamphetamine started at 10 months 
post-surgical intervention for CP and lasting for 24 months was shown to diminish continuous weight 
gain and stabilize body mass index [92]; importantly, spontaneous physical activity increased 
significantly. Even shorter periods of dextroamphetamine treatment caused a subjective improvement 
in daytime sleepiness [106]. Elfers and Roth also observed beneficial effects of central stimulating 
agents on weight development in CP patients [107].  
CP patients with hypothalamic obesity have a “parasympathetic predominance” of the autonomic 
nervous system induced by vagal activation and manifesting as daytime sleepiness, and reduced body 
temperature and heart rate [108]. Parasympathetic stimulation causes insulin secretion by way of direct 
activation of β cells as well as promotes adipogenesis. As insulin is an anabolic hormone, it has been 
suggested as an important driver of weight gain in hypothalamic obesity. Octreotide is a somatostatin 
analogue and thus causes reduction in insulin secretion. Lustig et al. used octreotide in a double-blind 
randomized controlled study in children with hypothalamic obesity and demonstrated moderate 
reductions in weight gain [95]. The authors showed that insulin levels during a proof-of-concept oral 
glucose tolerance test decreased without leading to major changes in glucose tolerance. This study  
was followed by a larger trial performed using octreotide LAR in 60 patients with cranial surgical 
interventions that led to hypothalamic obesity [109]. This 6-month intervention showed no efficacy in 
changing body mass index and the open label segment of this study was terminated earlier than 
planned due to an increased risk of gallstone formation.  
Initial experiences with bariatric surgery in severely obese CP patients achieved sufficient 
tolerability and short-term weight reduction [110–112]. An instant improvement of binge-eating 
behavior in patients with CP immediately after laparoscopic adjustable gastric banding (LAGB) was 
observed, but failed in long-term weight reduction. Nevertheless, weight stabilization could be 
achieved during regular follow-up monitoring [113].  
In a systematic review and meta-analysis of the literature, Bretault et al. [114] analyzed the 12 
months outcome after bariatric surgery for hypothalamic obesity due to CP and demonstrated that 
Roux-Y gastric-bypass, sleeve gastrectomy, and biliopancreatic diversion are the most efficient bariatric 
procedures for weight reduction in hypothalamic obesity of CP. However, treatment with invasive, 
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non-reversible bariatric methods is controversial in the pediatric population because of medical, 
ethical, and legal considerations [113,115,116]. 
Despite the availability of the above-mentioned promising therapeutic approaches, it must be 
emphasized that currently no generally accepted (pharmacological or bariatric) therapy for 
hypothalamic obesity in CP has been shown to be effective in randomized studies [117].  
6.8. Quality of Life, Neurocognitive Outcome and Psychosocial Functioning 
QoL in CP patients can be affected by both the tumor itself and the treatment received. Reports 
assessing psychosocial and physical functioning show variable results, ranging from excellent in  
a majority of subjects to impaired function in almost half of the patients [23,59,118–120]. The most 
common areas of difficulty reported include emotional and social functioning, with CP patients rating 
their psychosocial status to be lower than their physical health [59]. Other challenges included somatic 
complaints such as pain, reduced mobility, and self-care [43,59]. Behavioral questionnaires indicate  
a high rate of psychopathological symptoms, including depression, anxiety, and withdrawal. The most 
frequent problems in CP patients’ everyday functioning include difficulties in learning, unsatisfactory 
peer relationships, inability to control emotions, and concerns regarding physical appearance and body 
image [62,121]. However, eating behavior and the rate of eating disorders are similar when compared 
with BMI-matched controls [122]. 
Factors associated with worsening quality of survival outcomes as well as neurocognitive and 
psychosocial functioning include preoperative functional impairment and younger age at diagnosis; 
furthermore tumor characteristics including hypothalamic and third ventricle involvement at 
presentation and larger tumor volume. Treatment strategies have also been implicated, with worse 
outcomes for surgery alone compared to limited surgery followed by irradiation and for multiple 
operations for tumor recurrence. Neuroendocrine, neurological, and ophthalmological sequelae all 
adversely affect QoL outcome [23,24,43,56,59,118,119]. Hypothalamic neuroendocrine deficits were 
found to have the most important negative impact on social functioning, physical ability, and body  
image [59,71,119]. 
Long-term neurocognitive complications following treatment for CP include cognitive  
problems, particularly those affecting episodic memory, executive function, attention, and working 
memory [59,62,121,123–128]. In a recent report, Özyurt et al. [129] provided first evidence that 
hypothalamic damage impacts on neural correlates of memory retrieval in medial prefrontal cortex, 
indicating a less efficient use of a prefrontal area involved in executive control processes. The authors 
propose that the deactivation failure in the patients’ anterior rostral medial prefrontal cortex is related  
to an increased coupling with the thalamus and reflects a reduced efficiency to flexibly adapt to task 
demands [129]. 
Furthermore, long-term survivors of CP treated primarily with subtotal surgical resection followed 
by irradiation were also found to have educational and psychological deficits [62]. Neurocognitive 
deficits include slower cognitive speed, memory disturbances, attention problems, and behavioral 
instability [62,121,123,125,126,128,130]. While intact intellectual functioning has been reported in up 
to 82% of patients, visual memory is impaired despite normal visual-spatial abilities [62,121]. The 
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acquired deficits in higher cognitive processing such as attention problems are considered precursors to 
poor academic achievement.  
6.9. Survival and Late Mortality 
Survival rates in CP patients are generally high [7]. However, disease related mortality can occur 
even many years after treatment. Data regarding survival includes primarily surgically treated patients. 
The reported post-surgical 5-year overall survival is 88%–94% [33,58,71,118], and the reported  
10-year overall survival is 70%–92% [23,24,59,77,118], with a 20 year survival of 76%. Causes of late 
mortality include those directly related to the tumor or treatment such as chronic hypothalamic deficits, 
progressive disease with multiple recurrences, cerebrovascular disease, hormonal deficiencies, 
seizures, and non-alcoholic steatohepatitis leading to liver cirrhosis in some cases [24,56,58,59,77].  
A recent review reports on substantial long-term morbidity with hypopituitarism, increased 
cardiovascular risk, hypothalamic neuroendocrine, visual and neurological deficits, reduced bone 
health, and reduction in QoL and cognitive function. The standardized overall mortality rate varies 
from 2.88–9.28 in cohort studies. Patients with CP have a 3–19-fold higher cardiovascular mortality in 
comparison to the general population. Women with CP have an even higher risk [131]. 
6.10. Treatment Strategies for Prevention of Neuroendocrine Sequelae 
Despite high survival rates (87%–95%) in CP patients, research over the last several years reveals 
that long-term QoL is frequently impaired due to post-surgical late effects caused by the tumor’s close 
proximity to (or even anatomical entanglement with) optic structures and hypothalamic-pituitary axes. 
Radical surgery was the treatment of choice for several decades, with high reported rates of tumor 
control (65%–90%) in comparison with those obtained for incomplete resection (10%–50%) [42,132]. 
However, even at highly specialized and experienced surgical facilities, radical surgery can result in 
severe damage to the visual apparatus and hypothalamic-pituitary axes, behavioral disorders, and 
neurocognitive impairment [30].  
Accordingly, management of CP remains controversial. Radical surgical strategies with the 
intention at gross-total resection frequently result in severe sequelae due to neuroendocrine 
hypothalamic deficits. Severe obesity is a major manifestation of hypothalamic syndrome and has 
negative impact on quality of survival [11]. On the other hand, hypothalamus-sparing surgery might 
increase the need for reoperation and/or irradiation [50].  
An intracystic catheter insertion and subsequent instillation of substances inducing cyst shrinkage 
seems a beneficial strategy avoiding additional morbidity in cystic CP. Bartels et al. reported on 
outcome and neuroendocrine morbidity in six patients treated with cyst instillation of interferon alpha. 
None of the interferon-treated children suffered new endocrinological dysfunction, evidence of 
hypothalamic damage and none of them is obese [133,134]. 
Reports on long-term neuroendocrine outcome after “radiation therapy only” in CP are missing in 
the literature, presumably due to the rareness of “radiation therapy only”, and the necessity for long-term 
follow-up because of the delayed effects of irradiation on neuroendocrine function in such CP patients.  
KRANIOPHARYNGEOM 2000, a large multicenter observational study that analyzed CP patients 
from Germany, Austria and Switzerland came to the conclusion that radical surgery is not an 
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appropriate treatment strategy in CP patients with involvement of posterior hypothalamic  
structures [11,45,46]. KRANIOPHARYNGEOM 2007, a long-term study designed to analyze the 
appropriate time point of irradiation after incomplete resection, is currently focusing on patients’ QoL 
issues affected by the above-mentioned adverse effects (Figure 6). 
 
Figure 6. Study design of KRANIOPHARYNGEOM 2007 (www.kraniopharyngeom.net). 
Modified from [33], with kind permission from Thieme. 
Both studies also showed that the prognosis in long-term survivors is influenced by surgical 
expertise and explicitly recommend that surgical strategy be planned and performed by experienced 
surgeons, especially in light of the rarity of the disease and that treatment management of the tumors 
invading the hypothalamus has a strong influence on the prognosis of these patients [12,45,46]. A 
recent report of Elowe-Gruau et al. [36] analyzing two CP cohorts treated by the same highly 
experienced surgical team adds to the literature linking surgical experience and informed strategies to 
outcome results. These researchers are able to show that a limited surgery adapted to the degree of 
hypothalamic tumor involvement and highly respectful of hypothalamic structures, followed by 
adjuvant radiotherapy, does not lead to an increased rate of recurrence, decreases the risk of severe 
weight gain, and partially decreases the prevalence of endocrine deficiencies. Their findings support 
the efficacy and tolerability of irradiation as a salvage therapy in case of progressive residual CP. In 
their multivariate analysis, preoperative hypothalamic involvement and hypothalamus-sparing surgery 
independently predicted the presence of severe obesity at last follow-up [36]. In recent years, several 
grading systems of hypothalamic involvement have been published, which recommend  
hypothalamus-sparing surgical strategies in order to improve outcome and neuroendocrine sequelae in 
CP [13,28,36,45,46,69] (Table 1). 
reference evaluation of pre and postoperative imaging (MRI / CT) 
assessment of the degree of resection 








Treatment arm II 
 MRI in 3 months intervals after surgery 
 Reference assessment of MRI 
 progression (>25%): !  XRT  
 reference assessment of XRT plans 
 MRI at 3 months intervals after XRT 
 Reference assessment of MRI 
patients 




Treatment arm I 
 
 Initiation of external local XRT 4 months 
after surgery 
 Reference assessment of XRT plans  
 MRI at 3 months intervals after XRT 
 Reference assessment of MRI 
>
→
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Table 1. Novel grading systems and treatment algorithms for childhood-onset craniopharyngioma patients based on magnetic resonance 
imaging. Modified from [7], with kind permission of Endocrine Press. 
Author (Reference) n FU (year) Grade 0 (0°) Grade 1 (I°) Grade 2 (II°) Treatment Recommendation Outcome Parameters 
Puget [38] 65 3 no HI 
HI (distortion/elevation) with negligible 
hypothalamic damage, the 
hypothalamus is still visible 
tumor spread to the hypothalamus, 
which was no longer identifiable. 
0°: gross-total resection (GTR)  
I°: attempt at GTR; if not achieved:  
2nd surgery ± XRT  
II°: subtotal resection with hypothalamic 
preservation + XRT 
lower BMI and similar relapse rate 
in a prospective cohort treated acc. 
to algorithm compared with 
historical cohort 
Garre [13] n.a. n.a. no HI according to Puget et al. [38] according to Puget et al. [38] 
0° + I°: attempt at GTR by experienced 
surgeon; if not achieved: XRT  
II°: cyst drainage ± XRT (proton beam 
therapy at age <5 year) 
n.a. 
Müller [45,46] 120 3 no HI 
HI/lesion of the anterior hypothalamus 
not involving the MB and the 
hypothalamic area beyond MB 
HI/lesion of the anterior + posterior 
hypothalamic area, i.e., involving 
the MB and the area beyond MB 
0°: GTR  
I°: attempt at GTR; if not achieved: XRT  
II°: subtotal resection with hypothalamic 
preservation + XRT 
higher BMI and lower QoL in the 
II° cohort treated by GTR resulting 
in posterior hypothalamic lesions 
Flitsch [28] n.a. n.a. no HI 
according to Müller et al. [45,46], 
specifying sections below and above the 
diaphragm sellae 
according to Müller et al. [45,46] 
0°: GTR  
I°: attempt at GTR—transsphenoidal 
approach; if not achieved: XRT  
II°: subtotal resection with hypothalamic 
preservation—transcranial approach, 
followed by XRT 
n.a. 
Fjalldall [69] 42 20 no HI 
suprasellar growth, not towards or into 
the 3rd ventricle (non-TGTV) 
suprasellar growth towards or into 
the 3rd ventricle (TGTV) 
Non-TGTV: GTR  
TGTV: subtotal resection with 
hypothalamic preservation + XRT 
Lower cognitive performance in 
TGTV patients treated by GTR 
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Optimal care of CP is best provided in a multidisciplinary collaborative environment that includes 
experienced pituitary practitioners in not only neurosurgery and endocrinology, but also in radiation 
oncology, medical oncology, neuroophthalmology, neuroradiology, and neuropathology. McLaughlin 
et al. [135] provided the background and rationale for recognizing pituitary “centers of excellence” and 
suggested a voluntary verification process. Hoffmann et al. [12] recently analyzed changes in surgical 
strategy during the last 15 years by comparing a CP cohort treated between 2000 and 2006 with a more 
recent cohort treated between 2007 and 2013. The authors observed a change towards less aggressive 
surgical strategies (gross-total resections) during the last 15 years in childhood CP.  
7. Conclusions 
Risk-adapted surgical strategies at initial diagnosis of CP should aim at a maximal degree of 
resection keenly focused on respecting the integrity of optical and hypothalamic structures to prevent 
severe neuroendocrine deficits and therein minimize consequences that could negative impact patient 
QoL. In case of hypothalamic involvement, hypothalamus-sparing surgical strategies are recommended 
in order to prevent hypothalamic damage and associated severe neuroendocrine sequelae. Local 
irradiation of residual tumor is efficient in preventing tumor progression. Because initial hypothalamic 
tumor involvement, especially of posterior hypothalamic structures, has an a priori effect on the 
clinical course [21,46], CP should be recognized as a chronic disease requiring constant monitoring of 
the consequences and medical resources for treatment in order to provide not only optimal QoL for 
patients, but also to garner additional information with the intent of minimizing what at present are 
severe consequences of both the disease and its treatment. CP patients should be treated by specialized 
and experienced multidisciplinary teams [11,30,136].  
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